Skip to content
MatchScript
Menu

Evidence review

Does GLP-1 Medication Cause Hair Loss? What the Evidence Shows

Ozempic, Wegovy, Mounjaro, and Zepbound are all linked to hair shedding — here's what the dermatology research actually says, and when it grows back.

By The MatchScript Team, Matching & Recommendations Desk

Hair shedding is one of the most-searched GLP-1 side-effect questions, and unlike some viral drug-side-effect claims, this one has real evidence behind it. Here's what a 2025 dermatology cohort study and the reviews that followed it actually found, why it happens, and what to expect if it happens to you.

The evidence: a real, measurable signal

A 2025 retrospective cohort study published in the Journal of the American Academy of Dermatology looked specifically at hair loss in patients taking GLP-1 receptor agonist medications and found a real association — not just scattered anecdotes1. A systematic review the following year pulled together the evidence across studies and reached the same conclusion: hair shedding is a genuine, if underappreciated, effect associated with this drug class, occurring at a meaningfully higher rate than in the general population2. A separate clinical review aimed at helping dermatologists counsel patients confirmed the pattern and laid out how to manage it3, and a 2026 continuing-education review for dermatologists put GLP-1-associated hair loss alongside other dermatologic effects clinicians should now watch for as this drug class became widely prescribed4.

It's telogen effluvium — a reaction to rapid change, not the drug attacking hair

The mechanism described across this literature is telogen effluvium: a stress-triggered shift where more hair follicles than usual enter the shedding (telogen) phase at once, usually two to four months after the triggering event13. This is the same pattern seen after major surgery, a severe illness, a crash diet, or significant unintentional weight loss from any cause — it's a recognized response to the body undergoing rapid metabolic and nutritional change, not a hair follicle being directly poisoned by the medication12. That distinction matters: it's the speed and scale of weight loss and the associated shifts in nutrient intake that appear to drive it, which is consistent with reports across all the GLP-1 molecules rather than one specific drug24.

Who it happens to, and how bad it gets

It isn't universal. The reviews describe it as a noticeable minority of patients on GLP-1 therapy, generally correlating with faster or larger weight loss and, plausibly, with inadequate protein or micronutrient intake during the loss phase13. It typically presents as diffuse thinning rather than patchy bald spots, most visible when you gather a comb full of shed strands rather than as a sudden dramatic change.

Is it temporary?

Telogen effluvium is, by definition, a temporary shift in the hair cycle rather than permanent follicle damage, and the reviews describe it as generally self-limited, typically resolving within several months once weight stabilizes and nutrition normalizes23. That said, "temporary" in hair-cycle terms can still mean months of visibly thinner hair before it recovers, which is understandably distressing in the moment even though the underlying prognosis is good.

What helps

The clearest, evidence-aligned levers are the boring ones: adequate protein intake and a generally nutrient-complete diet during weight loss, since caloric deficits paired with low protein intake are a recognized aggravator of telogen effluvium13. This is the same advice that helps limit muscle loss during treatment — see GLP-1 and muscle loss — because both are downstream of the same rapid-change stress on the body. If shedding is significant or doesn't improve after your weight stabilizes, it's worth a conversation with your prescriber or a dermatologist to rule out other causes and discuss options like biotin or minoxidil, which some clinicians recommend though the evidence specific to GLP-1-associated shedding is still limited.

Worth weighing when you choose a provider

A provider whose intake actually screens for nutrition and pace — not just prescribes and ships — is better positioned to help you avoid the more severe end of this. It's one more argument for real clinician support over the cheapest possible plan; see our checklist for choosing a GLP-1 provider and the broader rundown of side effects worth watching for in our GLP-1 side effects guide.

The honest bottom line: hair shedding on a GLP-1 is real, documented in the dermatology literature, driven by the stress of rapid weight and nutritional change rather than the drug itself attacking hair, and typically resolves on its own once your weight and eating pattern stabilize.

Frequently asked questions

Does Ozempic, Wegovy, Mounjaro, or Zepbound cause hair loss?

Research shows a real association between GLP-1 receptor agonist medications and hair shedding, documented in a 2025 dermatology cohort study and confirmed by systematic reviews since. It's reported across the drug class rather than being specific to one brand or molecule.

Why does GLP-1 medication cause hair loss?

The mechanism is telogen effluvium — a stress response where more hair follicles than normal shift into the shedding phase at once, usually 2–4 months after a triggering event. It's the same pattern seen after major weight loss from any cause, illness, or surgery, driven by rapid metabolic and nutritional change rather than the drug directly damaging follicles.

Is GLP-1-related hair loss permanent?

No — telogen effluvium is a temporary shift in the hair cycle, not permanent follicle damage, and the evidence describes it as generally self-limited once weight stabilizes and nutrition normalizes. It can still mean months of visibly thinner hair before it fully recovers.

How can I reduce the risk of hair shedding on a GLP-1?

Adequate protein intake and a nutrient-complete diet during weight loss are the clearest evidence-aligned levers, since caloric deficits combined with low protein intake are a recognized aggravator of telogen effluvium. If shedding is significant or persists, talk to your prescriber or a dermatologist.

References

  1. Burke O, Sa B, Cespedes DA, et al. (2025). Glucagon-like peptide-1 receptor agonist medications and hair loss: A retrospective cohort study. Journal of the American Academy of Dermatology. https://pubmed.ncbi.nlm.nih.gov/39863171/
  2. Gupta AK, Teasell EM, Economopoulos V, et al. (2026). GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling. Science Progress. https://pubmed.ncbi.nlm.nih.gov/41998799/
  3. Piraccini BM, Vañó-Galván S, Blume-Peytavi U, et al. (2026). Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes. Dermatology and Therapy. https://pubmed.ncbi.nlm.nih.gov/42249225/
  4. Narla S, Narla RR (2026). JAAD CME Part 2: Clinical Evidence and Safety Considerations for GLP-1 Receptor Agonists in Dermatology. Journal of the American Academy of Dermatology. https://pubmed.ncbi.nlm.nih.gov/41698604/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Continue reading